Cuu Long Pharmaceutical JSC (HOSE:DCL)

HOSE:DCL Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jan 1, 2021
Revenue	1,409,133	1,306,797	1,143,946	1,015,686	703,634	671,246
Revenue Growth (YoY)	16.52%	14.24%	12.63%	44.35%	4.83%	-10.74%
Cost of Revenue	1,192,560	1,102,093	934,032	733,585	493,482	483,609
Gross Profit	216,573	204,704	209,914	282,100	210,152	187,637
Selling, General & Admin	148,135	144,874	139,188	153,815	123,371	139,733
Operating Expenses	148,135	144,874	139,188	153,815	123,371	139,733
Operating Income	68,438	59,830	70,726	128,285	86,781	47,904
Interest Expense	-35,912	-25,494	-30,530	-39,627	-36,264	-33,264
Interest & Investment Income	16,632	34,279	39,667	52,712	51,929	71,400
Currency Exchange Gain (Loss)	-24.2	152.37	-2,705	77.03	-90.68	468.88
Other Non Operating Income (Expenses)	9,824	9.56	953.02	94.19	6,058	-564.86
EBT Excluding Unusual Items	58,958	68,777	78,111	141,542	108,412	85,944
Gain (Loss) on Sale of Investments	-	-	-	-	1,872	-
Pretax Income	58,958	68,777	78,111	141,542	110,284	85,944
Income Tax Expense	16,232	14,631	15,976	28,628	22,528	17,017
Earnings From Continuing Operations	42,726	54,145	62,134	112,914	87,756	68,928
Minority Interest in Earnings	-590.78	-574.4	-416.96	-1,273	-1,796	-2,537
Net Income	42,135	53,571	61,717	111,641	85,961	66,391
Preferred Dividends & Other Adjustments	-1,000	-	2,000	3,000	2,000	2,110
Net Income to Common	43,135	53,571	59,717	108,641	83,961	64,281
Net Income Growth	-32.75%	-13.20%	-44.72%	29.87%	29.48%	-24.96%
Shares Outstanding (Basic)	73	73	73	70	57	57
Shares Outstanding (Diluted)	73	73	73	70	57	57
Shares Change (YoY)	1.03%	-	4.11%	22.02%	1.17%	-24.64%
EPS (Basic)	587.34	733.44	817.59	1548.46	1460.20	1131.05
EPS (Diluted)	586.91	733.00	817.59	1548.00	1460.00	1131.00
EPS Growth	-31.90%	-10.35%	-47.18%	6.03%	29.09%	-7.94%
Free Cash Flow	-139,972	-103,037	-200,343	-683,099	-123,174	-8,582
Free Cash Flow Per Share	-1905.92	-1410.67	-2742.89	-9736.25	-2142.18	-151.01
Gross Margin	15.37%	15.67%	18.35%	27.77%	29.87%	27.95%
Operating Margin	4.86%	4.58%	6.18%	12.63%	12.33%	7.14%
Profit Margin	3.06%	4.10%	5.22%	10.70%	11.93%	9.58%
Free Cash Flow Margin	-9.93%	-7.89%	-17.51%	-67.25%	-17.51%	-1.28%
EBITDA	113,175	97,686	109,004	166,420	121,054	76,184
EBITDA Margin	8.03%	7.47%	9.53%	16.38%	17.20%	11.35%
D&A For EBITDA	44,737	37,856	38,278	38,135	34,273	28,280
EBIT	68,438	59,830	70,726	128,285	86,781	47,904
EBIT Margin	4.86%	4.58%	6.18%	12.63%	12.33%	7.14%
Effective Tax Rate	27.53%	21.27%	20.45%	20.23%	20.43%	19.80%
Revenue as Reported	1,246,282	1,143,946	-	1,015,686	703,634	671,246

Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.